You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨亞盛醫藥-B(6855.HK)高開5% 與信達生物達成戰略合作
格隆匯7月15日丨亞盛醫藥-B(6855.HK)高開5%,報55.6港元創其上市以來新高,總市值141億港元。亞盛醫藥昨日與信達生物共同宣佈達成重磅戰略合作。合作內容包括雙方就亞盛醫藥核心品種三代BCR-ABL抑制劑Olverembatinib (HQP1351)進行在中國的共同開發和共同商業推廣;就亞盛醫藥在研創新藥Bcl-2抑制劑Lisaftoclax (APG-2575)與信達生物與禮來製藥共同開發的抗CD20單克隆抗體達伯華®、信達生物在研抗CD47單克隆抗體letaplimab(IBI188)展開的臨牀合作。此外,信達生物將按照每股44港幣認購亞盛醫藥價值5000萬美元的普通股,並獲股權認購權證,有權以每股57.2港幣的價格認購亞盛醫藥價值5000萬美元的普通股。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account